Article Type

Original Study


Objective The aim of this study was to evaluate the postoperative outcome and the recurrence rate after primary pterygium excision using preoperative subpterygial bevacizumab injection at the time of surgical removal as against 2 weeks before surgery. Background Recurrence after pterygium excision represents a challenge for ophthalmologists and is considered to be the most common postoperative complication. Several techniques have evolved in a trial to overcome the high rate of postoperative recurrence. However, none proved to be totally effective. Patients and methods Forty eyes with primary pterygium were divided into two groups. Group A eyes (included 20 eyes) were operated upon with pterygium excision after subpterygial injection of bevacizumab. Group B eyes (included 20 eyes) were operated upon with pterygium excision 2 weeks after subpterygial injection of bevacizumab. Pterygium regrowth over the cornea for 1 mm or more was considered as a recurrence. Results The follow-up period was 6 months. In group A, recurrence was reported in two (10%) eyes, whereas in group B, recurrence was reported in one (5%) eye. No serious postoperative complications were reported. There was no statistically significant difference between the two groups regarding the recurrence rate and the complication rate. Conclusion Both techniques used in the current study proved to be effective in reducing the recurrence rate after excision of the primary nasal pterygium with minimal postoperative complications. Injection of bevacizumab 2 weeks before had a better effect on decreasing the pterygium vascularity, which minimized bleeding during operation in addition to decreasing the recurrence rate, according to this study.